Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IONS
  • CUSIP: 46433010
  • Web:
  • Market Cap: $5.75 billion
  • Outstanding Shares: 123,965,000
Average Prices:
  • 50 Day Moving Avg: $44.42
  • 200 Day Moving Avg: $44.96
  • 52 Week Range: $19.59 - $57.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -331.07
  • P/E Growth: -3.03
Sales & Book Value:
  • Annual Revenue: $420.05 million
  • Price / Sales: 13.68
  • Book Value: $1.63 per share
  • Price / Book: 28.44
  • EBIDTA: $33.51 million
  • Net Margins: -77.30%
  • Return on Equity: -120.60%
  • Return on Assets: -21.09%
  • Debt-to-Equity Ratio: 3.03%
  • Current Ratio: 6.83%
  • Quick Ratio: 6.75%
  • Average Volume: 1.87 million shs.
  • Beta: 2.54
  • Short Ratio: 4.9

Frequently Asked Questions for Ionis Pharmaceuticals (NASDAQ:IONS)

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its quarterly earnings results on Tuesday, May, 9th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.13. The company had revenue of $110.30 million for the quarter, compared to the consensus estimate of $86.03 million. Ionis Pharmaceuticals had a negative return on equity of 120.60% and a negative net margin of 77.30%. The company's revenue for the quarter was up 199.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.52) EPS. View Ionis Pharmaceuticals' Earnings History.

Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?

13 brokers have issued 12-month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $17.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $41.73 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

What are analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

  • 1. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
  • 2. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
  • 3. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (2/27/2017)
  • 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)
  • 5. Jefferies Group LLC analysts commented, "Pipeline update call focuses on volanesorsen, IONIS-GCGR-Rx & IONIS-FXI- Rx; and BIIB-partnered IONIS-DMPK-2.5-Rx discontinued due to inadequate potency in muscle in Ph1/2. Beyond highly anticipated Spinraza launch (our 2021E sales of $1.6B vs. BIIB cons of $1.4B, implying royalties to IONS of ~$250M), we view current pipeline products unlikely to drive further meaningful appreciation in IONS shares from its already hefty valuation (EV of ~$5.5B)." (1/6/2017)

Are investors shorting Ionis Pharmaceuticals?

Ionis Pharmaceuticals saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 13,332,120 shares, an increase of 15.9% from the April 13th total of 11,507,042 shares. Based on an average daily volume of 1,428,282 shares, the days-to-cover ratio is currently 9.3 days. Currently, 10.9% of the company's stock are sold short.

Who are some of Ionis Pharmaceuticals' key competitors?

Who owns Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (7.63%), Wellington Management Group LLP (7.56%), Baillie Gifford & Co. (6.32%), BB Biotech AG (6.03%) and BlackRock Inc. (5.30%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co. NY, Baillie Gifford & Co., Waddell & Reed Financial Inc., Scout Investments Inc., First Trust Advisors LP, Renaissance Technologies LLC, Pinnacle Associates Ltd. and Tocqueville Asset Management L.P.. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Patrick R O'neil, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, State Street Corp, BB Biotech AG, Vanguard Group Inc., FMR LLC, Gotham Asset Management LLC and Credit Suisse AG. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy Ionis Pharmaceuticals stock?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ionis Pharmaceuticals stock cost?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $46.35.

Analyst Ratings

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (?)
Ratings Breakdown: 2 Sell Ratings, 5 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.31)
Consensus Price Target: $41.73 (9.97% downside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
5/17/2017Leerink SwannReiterated RatingOutperform$47.00 -> $45.00MediumView Rating Details
5/17/2017Needham & Company LLCReiterated RatingBuy$64.00LowView Rating Details
5/11/2017BMO Capital MarketsBoost Price TargetOutperform$32.00 -> $35.00HighView Rating Details
5/10/2017Piper Jaffray CompaniesSet Price TargetBuy$66.00 -> $51.00LowView Rating Details
3/10/2017Goldman Sachs Group IncDowngradeNeutral -> Sell$28.00 -> $25.00HighView Rating Details
1/6/2017Jefferies Group LLCReiterated RatingSell$17.00N/AView Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/AView Rating Details
12/27/2016LaidlawBoost Price TargetBuy$59.00 -> $65.00N/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$35.00N/AView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
8/2/2016Barclays PLCBoost Price TargetEqual Weight$26.00 -> $41.00N/AView Rating Details
8/2/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$37.00 -> $37.00N/AView Rating Details
6/22/2015Deutsche Bank AGSet Price TargetBuy$78.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Earnings History by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.10)$0.03$86.03 million$110.30 millionViewListenView Earnings Details
2/28/2017Q416($0.20)$0.33$97.47 million$160.30 millionViewListenView Earnings Details
11/9/2016Q316$0.07$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
2017 EPS Consensus Estimate: ($0.13)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.06)$0.16$0.05
Q2 20172($0.38)$0.19($0.10)
Q3 20172($0.31)$0.22($0.05)
Q4 20172($0.30)$0.23($0.04)
(Data provided by Zacks Investment Research)


Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 87.76%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Patrick R O'neilSVPSell650$48.75$31,687.50View SEC Filing  
4/25/2017Stanley T CrookeChairmanSell16,500$47.81$788,865.00View SEC Filing  
4/24/2017Patrick R O'neilSVPSell500$45.00$22,500.00View SEC Filing  
4/19/2017Stanley T CrookeChairmanSell5,500$43.25$237,875.00View SEC Filing  
4/13/2017Stanley T CrookeChairmanSell22,000$40.69$895,180.00View SEC Filing  
4/12/2017Patrick R O'neilSVPSell1,000$40.07$40,070.00View SEC Filing  
3/3/2017C Frank BennettSVPSell5,000$55.00$275,000.00View SEC Filing  
3/1/2017B Lynne ParshallCOOSell4,625$49.26$227,827.50View SEC Filing  
3/1/2017Patrick R O'neilSVPSell1,500$49.29$73,935.00View SEC Filing  
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.34View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.58View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.17View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.69View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.78View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.00View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.00View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.40View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.40View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.00View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.00View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.00View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.00View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.00View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.00View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.00View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.00View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.00View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.00View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ionis Pharmaceuticals (NASDAQ:IONS)
Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
DateHeadline logoIonis Pharma (IONS) Announces Publication in NEJM of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects - May 26 at 2:27 AM logoAkcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects - May 26 at 2:27 AM logoIonis Pharmaceuticals' (IONS) "Market Perform" Rating Reiterated at Cowen and Company - May 22 at 10:54 AM logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : May 19, 2017 - May 19 at 10:30 AM logoLeerink Swann Analysts Cut Earnings Estimates for Ionis Pharmaceuticals Inc (IONS) - May 18 at 2:48 PM logoIonis Pharmaceuticals Inc (IONS) Earns "Buy" Rating from Needham & Company LLC - May 17 at 10:26 PM logoIonis Pharmaceuticals Inc (IONS) Rating Reiterated by Leerink Swann - May 17 at 12:16 PM logoBiotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal - May 17 at 9:56 AM logoIonis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS ... - May 16 at 11:00 AM logoToday's Research Reports on Stocks to Watch: Ionis Pharmaceuticals and Exact Sciences Corporation - May 16 at 11:00 AM logoIonis Pharma (IONS) Reports Phase 3 NEURO-TTR Study of Inotersen Met Both Primary Endpoints - May 15 at 5:28 PM logoHere's Why Shares of Ionis Pharma (IONS) are Falling Today - May 15 at 5:28 PM logoWhy Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today - May 15 at 1:25 PM logoIonis Pharmaceuticals Inc (IONS) Shares Fall on Drug Safety Concerns - May 15 at 11:20 AM logoIonis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints - May 15 at 10:51 AM logoWhy Ionis Pharma Is Sinking Despite Solid Late-Stage Results - May 15 at 10:51 AM logoEdited Transcript of IONS earnings conference call or presentation 9-May-17 3:30pm GMT - May 14 at 5:50 PM logoIonis Pharmaceuticals Inc (IONS) Given a $51.00 Price Target by Piper Jaffray Companies Analysts - May 13 at 5:14 PM logoQ3 2017 EPS Estimates for Ionis Pharmaceuticals Inc (IONS) Lowered by Leerink Swann - May 12 at 11:22 AM logoJefferies Group Equities Analysts Lower Earnings Estimates for Ionis Pharmaceuticals Inc (IONS) - May 12 at 9:37 AM logoIonis Pharmaceuticals Inc (IONS) Stock Rating Reaffirmed by BMO Capital Markets - May 11 at 11:28 PM logoIonis Pharmaceuticals Provides Corporate Update at 2017 Annual Meeting of Stockholders - May 11 at 6:31 PM logoIonis Pharmaceuticals Inc.'s First Royalties Roll In - May 11 at 4:16 PM logoQ2 2017 EPS Estimates for Ionis Pharmaceuticals Inc Raised by Leerink Swann (IONS) - May 11 at 8:34 AM logoShort Interest in Ionis Pharmaceuticals Inc (IONS) Grows By 15.9% - May 11 at 7:12 AM logoWhy Ionis is Tumbling - May 10 at 6:19 PM logoWhy Ionis (IONS) Might Surprise This Earnings Season - Yahoo Finance - May 10 at 1:17 PM logoIonis Pharmaceuticals to Present at Bank of America Merrill Lynch 2017 Healthcare Conference - PR Newswire (press release) - May 10 at 1:17 PM logoIonis Pharmaceuticals to Present at Bank of America Merrill Lynch 2017 Healthcare Conference - May 10 at 1:17 PM logoIonis Reports Financial Results and Highlights for First Quarter 2017 - May 9 at 5:43 PM logoIonis Pharmaceuticals (IONS) Beats on Q1 Earnings - May 9 at 5:43 PM logoInvestor Network: Ionis Pharmaceuticals, Inc. to Host Earnings Call - May 9 at 5:43 PM logoAkcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors - May 9 at 5:43 PM logoIonis Pharmaceuticals Inc (IONS) Issues Quarterly Earnings Results - May 9 at 4:50 PM logoIonis Pharmaceuticals (IONS) Beats on Q1 Earnings - Nasdaq - May 9 at 12:23 PM logoIonis Pharmaceuticals tops 1Q profit forecasts - May 9 at 10:49 AM logoWhy Ionis (IONS) Might Surprise This Earnings Season - May 8 at 5:36 PM logoIonis Pharmaceuticals Inc (IONS) Given Average Rating of "Hold" by Analysts - May 8 at 11:30 AM logo$137.78 Million in Sales Expected for Ionis Pharmaceuticals Inc (IONS) This Quarter - May 6 at 9:02 AM logoZacks: Analysts Expect Ionis Pharmaceuticals Inc (IONS) to Post -$0.04 EPS - May 4 at 1:32 PM logoWhat's in the Cards for Ionis (IONS) this Earnings Season? - May 4 at 11:15 AM logoIonis Pharmaceuticals Inc (IONS) SVP Patrick R. O'neil Sells 650 Shares - May 4 at 1:26 AM logoIonis Pharmaceuticals Inc (IONS) Receives Outperform Rating from BMO Capital Markets - May 1 at 12:14 AM logoIonis Pharmaceuticals: Big Data Coming Soon - Motley Fool - April 28 at 6:56 PM logoIonis Pharmaceuticals to Hold First Quarter 2017 Financial Results Webcast - Yahoo Finance - April 28 at 6:56 PM logoIonis Pharmaceuticals Inc to Post Q1 2017 Earnings of ($0.06) Per Share, Jefferies Group Forecasts (IONS) - April 28 at 7:48 AM logoStanley T. Crooke Sells 16,500 Shares of Ionis Pharmaceuticals Inc (IONS) Stock - April 27 at 9:08 PM logoIonis Pharmaceuticals Inc (IONS) SVP Patrick R. O'neil Sells 500 Shares - April 26 at 9:14 PM logoIONS Crosses Above Average Analyst Target - April 26 at 7:22 PM logoIonis Pharmaceuticals to Hold First Quarter 2017 Financial Results Webcast - April 26 at 7:22 PM



Ionis Pharmaceuticals (IONS) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff